A Phase 2 clinical trial of Bionomics' (BNO) therapeutic...

A Phase 2 clinical trial of Bionomics' (BNO) therapeutic candidate BNC210 has commenced. The mid-stage trial will evaluate the effect of BNC210 on the resolution of agitation in hospitalised elderly patients and assess the safety and tolerability of BNC210 in this patient population. Agitated behavioural disturbance in elderly patients is a major unmet clinical problem, occurring acutely in hospitalised patients and chronically in nursing home residents. These agitated behaviours can cause distress for the patient, distress to other patients, and can interfere with the therapeutic procedures for which the patient was hospitalised.

http://crweworld.com/article/news-p...clinical-trial-for-the-treatment-of-agitation